
Medical AI company
Lucida Medical
Developer of Pi, AI software that analyses prostate MRI scans to help diagnose prostate cancer.
Company overview
Lucida Medical develops Pi, AI software that analyses MRI scans to support the diagnosis of prostate cancer within the prostate cancer pathway. The company was co-founded in 2019 by Evis Sala and Antony Rix.
- Founded
- 2019 source
- Company type
- AI Technology Developer, Research or Emerging Startup
In its own words: “Lucida Medical develops Pi, AI software that analyses MRI scans with expert level performance to help diagnose prostate cancer.” source
AI products and platforms
- PiAI-powered
AI analysis of prostate MRI for prostate cancer diagnosis
Product page ↗
Technology categories
Clinical applications
- prostate cancer pathway
Official sources
Last verified 29 October 2026 against the sources above.
Questions about Lucida Medical
Does Medical AI have to explain how it reaches its outputs?
Not always in a technical sense, but transparency about the product is increasingly expected. Many machine learning models cannot give a simple step-by-step reason for each output, so regulators focus on clear information for users: intended use, inputs, how the model was developed and tested, performance, and known limitations.
In the US, one of the criteria for clinical decision support to fall outside device regulation is that a healthcare professional can independently review the basis for its recommendations. FDA has also published transparency principles for machine learning devices with Health Canada and MHRA.
For buyers, a vendor's ability to document how its model works and where it fails is often more useful than heat maps or confidence scores alone.
How is radiology AI different from general diagnostic imaging software?
General diagnostic imaging software stores, displays and manipulates images, for example PACS viewers, 3D reconstruction or measurement tools operated by the user. Radiology AI adds automated analysis that produces its own output, such as a detection, triage flag or quantitative result.
The distinction matters for evaluation:
- Viewing and processing tools are judged mainly on image quality, usability and integration.
- AI analysis tools also need evidence on accuracy, populations studied, failure modes and monitoring.
Both can be regulated medical devices depending on intended use; in the US many image management and processing functions fall under device classifications. Many vendors now combine the two, so ask which functions are AI-based and which are covered by a regulatory authorization.
What is AI image reconstruction and denoising?
AI image reconstruction and denoising use deep learning to produce clearer images from raw scanner data or to reduce noise and artifacts, for example in CT or MRI. Vendors often position these tools as supporting lower-dose or faster scanning protocols.
Unlike detection software, these tools change the image the clinician reads rather than adding a finding. Questions to ask include:
- Is the function built into the scanner or a separate software product?
- Which scanners, protocols and body regions is it authorized for?
- How was diagnostic image quality evaluated, and could fine detail be lost or altered?
These functions are typically regulated as part of the imaging device or as image processing software, depending on the product and market.